MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and protein synthesis. To characterize functions of miRNAs and to assess their potential applications, we carried out an integrated multi-omics analysis to study miR-145, a miRNA that has been shown to suppress tumor growth. We employed gene expression profiling, miRNA profiling and quantitative proteomic analysis of a pancreatic cancer cell line. In our transcriptomic analysis, overexpression of miR-145 was found to suppress the expression of genes that are implicated in development of cancer such as ITGA11 and MAGEA4 in addition to previously described targets such as FSCN1, YES1
Introduction
MicroRNAs (miRNAs) are short (18-24 nt) non-coding RNAs that play roles in posttranscriptional gene regulation. Mature miRNAs associate with the RNA-induced silencing complex and bind to the 3'-untranslated region (3'UTR) of mRNAs. This leads to repression of translation and/or degradation of transcripts, influencing diverse biological processes ranging from gametogenesis and embryonic development to tissue repair and aging. [1] [2] [3] [4] Evidence for a link between miRNAs and development of cancers is accumulating. 5, 6 Dysregulation of miRNAs has been associated with multiple hallmarks of cancer including proliferation, abnormal migration and aberrant angiogenesis. [7] [8] [9] Depending on their effects on tumor growth, miRNAs can be categorized as oncogenic miRNAs or tumor suppressor miRNAs. Identifying targets of these miRNAs and unraveling their networks can improve our understanding of cancers and potentially lead to novel therapeutic strategies.
miR-145 has low to absent expression in several cancer types and is most abundant in cells of mesenchymal origin. 10 Overexpressing miR-145 therapeutically has hindered tumor growth in model systems. 11 For example, downregulation of miR-145 has been reported in leukemia, lymphoma, craniopharyngioma and various human solid tumors, including pancreatic, colon, esophageal, lung, breast, prostate, liver and bladder cancers. [12] [13] [14] [15] [16] [17] [18] [19] [20] In some cancer cell lines, p53 can upregulate transcription and posttranscriptional maturation of miR-145 in response to DNA damage. 21, 22 In xenograft models, the reconstitution of miR-145 was demonstrated to inhibit tumor growth of pancreatic, hepatic and endometrial cancer. 14, 23, 24 Given that miRNAs can exert their effects in biologic networks by regulating a large number of targets, it is necessary to identify miR-145 targets in a global fashion.
Different approaches have been employed to identify miRNA targets such as gene expression microarrays, RNA cross-linking immunoprecipitation and bioinformaticsbased prediction algorithms, among others. One of the major limitations of transcriptomics-based methodologies is that changes in protein abundance are missed.
Bioinformatics approaches generate many false-positive predictions of miRNA targets.
Given the known effects of miRNAs on translation, quantitative proteomics serves as a complementary technology to measure the impact of miRNAs on intracellular protein levels. 25, 26 To identify the targets of miR-145 and thus to identify the mechanisms of tumor suppression by miR-145, we carried out stable isotope labeling by amino acids in cell culture (SILAC)-based proteomic profiling along with transcriptomic analysis to quantify the global changes subsequent to miR-145 overexpression in a pancreatic cancer cell line, MiaPaCa-2. Integrating the quantitative results from mRNA microarrays, miR microarrays and SILAC revealed previously unreported targets of miR-145 as well as provided novel insights into the tumor suppressive mechanisms of miR-145.
Results and discussion

Impact of miR-145 on mRNAs
miRNA-mediated post-transcriptional regulation of gene expression can result in the destabilization of target mRNA transcripts and hence decreased transcript abundance.
Identifying the number and extent of mRNA transcripts that are downregulated by a miRNA in this fashion provides a foundation to understand miRNA-gene networks.
Unlike bioinformatic predictions of miRNA targets, which often predict hundreds of transcripts targeted by each miRNA, the extent of experimental transcriptomic changes caused by miRNA overexpression are commonly lower by an order-of-magnitude. 27 To obtain a global view of transcriptomic changes, we carried out mRNA microarray analysis 48 hours after transfection of miR-145 into MiaPaca-2 cells. Fold-changes of 18,522 genes were quantified (Table S1 ). Most of the detected transcripts did not change significantly ( Figure 1A) . Expression of 73 genes was downregulated ≥1.5-fold after miR-145 transfection while that of 11 genes was upregulated ≥1.5-fold (false discovery rate (FDR)<1%, Table S2 ). Notably, of the 73 downregulated genes, 9 mRNAs were previously described as targets of miR-145 including PODXL, ABRACL (C6orf115), NDUFA4, FSCN1, GMFB, AP1G1, YES1, TMEM9B and CBFB. [28] [29] [30] 30 Among the genes identified as miR-145 targets in our analyses, there are some that could explain miR-145 tumor suppressive activity. For instance, podocalyxin-like 1 (PODXL), is a transmembrane glycoprotein which is functionally associated with multiple cancers including breast, colon and pancreatic cancer.31-33 Fascin 1 (FSCN1) is involved in the 
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assembly of polymerized actin and forms filipodia critical for cell motility and cancer migration. 34, 35 In addition to these miR-145 targets, we observed two mRNAs linked to cancer development that were downregulated by miR-145. Melanoma antigen family A 4 (MAGEA4) is a cancer/testis antigen whose germ-line expression is reactivated in cancers and belongs to the family proteins that may block binding of p53 to DNA. 36, 37 Overexpression of MAGEA4 has been previously noted in hepatocellular carcinoma. 38 Importantly, cytotoxic T cell-mediated immunotherapy against MAGEA4 has shown efficacy in treatment of Hodgkin lymphoma. 39 The other molecule linked to cancer that was downregulated by miR-145 is integrin alpha 11 (ITGA11), which is overexpressed in non-small cell lung cancer and is known to enhance tumorigenicity by dysregulating tumor-stromal interaction.
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Regulation of miRNAs by miR-145
It is documented in various cancers that the expression of miR-145 changes in parallel with that of certain other miRNAs. 13, 20, 28, [41] [42] [43] [44] [45] [46] Figure 1B and Table S3 ). Seven miRNAs increased >2-fold while only let-7e decreased > 2-fold (FDR<3.0E-6, Table S4 ). Upregulation of miR-124 (8.7-fold), miR-133b (5.2-fold) and miR-125a-3p (3.0-fold) might be related to the observed effect of miR-145 as a tumor suppressor, and their expression often changed concomitantly with that of miR-145 in other cancers as discussed below (Table S4 ). For instance, miR-124 is also known as a multifaceted tumor suppressor miRNA. In glioblastoma multiforme stem cells, miR-124 has been shown to cause cell cycle arrest and induce differentiation. 47 In cholangiocarcinoma, cancer cell migration and invasion were inhibited by miR-124 overexpression. 48 In esophageal squamous cell carcinoma, where miR-133b shares FSCN1 as a target with miR-145, inhibition of cancer cell growth and invasion was observed in miR-133b overexpression. 28 In non-small cell lung cancer and gastric cancer, downregulation of miR-125a-3p correlates with clinical cancer invasion in adjacent lymph nodes. 49, 50 This suggests a potential role of miR-125a-3p in inhibiting migration of cancer cells. Taken together, miR-145 upregulates an ensemble of miRNAs, including three that have previously been reported as tumor suppressors;
adding to potential mechanisms contributing to the tumor suppressive properties of miR-145 in cancers.
Impact of miR-145 on the proteome
Another important mechanism for miRNA-mediated regulation of targets is to repress protein synthesis that can occur with or without alteration of mRNA transcript abundance. 51 In other words, measuring protein abundance not only reflects the ultimate impact of miRNAs on translation but also complements what transcriptomic analysis alone is not able to reveal. We decided to use quantitative proteomics to characterize proteome dynamics subsequent to miR-145 overexpression. The strategy for our SILAC proteomics study in the MiaPaca-2 pancreatic cancer cell line is depicted in Figure 2 . The cells labeled with heavy amino acids were transfected with miR-145 while those cultured in the regular (light) medium were transfected with a scrambled RNA control. Forty-eight hours after transfection, the cells were harvested and proteins were extracted. We mixed lysates from heavy and light samples and subjected the samples to four different fractionation methods − in-gel digestion, strong cation exchange, off-gel peptide fractionation and off-gel protein fractionation. Via liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis on an LTQ-Orbitrap Velos mass spectrometer, we identified ~20,000 peptides corresponding to 2,905 proteins at a 1% FDR (Table S5 and Figure S1 ). Ninety percent (2,605) of these proteins were quantifiable ( Figure 3A ).
Membranous and nuclear proteins comprised 13.3% and 15.0%, respectively, of the total.
While the majority of the proteome remained unchanged, 160 (6.1%) proteins were downregulated ≥1.5-fold and 43 (1.7%) proteins were upregulated ≥1.5-fold. The representative lists of the most regulated proteins are given in Table S6 . Based on TarBase 6.0, a database of experimentally validated miRNA targets, six of the downregulated proteins had been previously identified as miR-145 targets including FSCN1, SWAP70, YES1, TPM3, AP1G1 and PODXL. 28, 52 In addition, based on SILAC 57 Higher expression of RPA1 is also linked to esophageal cancer and associated with lymph node metastasis. 58 Minichromosome maintenance protein 2 (MCM2) is a subunit of the heterohexameric DNA replication machinery, which is tightly regulated through cell cycle. It serves as a histopathological cancer biomarker in pancreaticobiliary cancer, colon cancer, retinoblastoma and lung cancer.59-62 ATP-binding cassette subfamily C member 1 (ABCC1), also known as multidrug resistance-associated protein 1, is a neutral and anion efflux pump on plasma membranes that confers chemoresistance in leukemias and solid cancers. 63 Expression of ABCC1 is also increased in pancreatic cancer. 64 Serine palmitoyltransferase 1 (SPLTC1) participates in sphingolipid metabolism, and its activity is elevated in endometrial cancer tissue. 65 To validate these novel miR-145 candidate targets along with known targets, we employed luciferase-3'UTR assays to examine the effect of miR-145 overexpression on these targets, several of which showed significant repression (miR-145/control): FSCN1, DIAPH1, PRPSAP2, RPA1, RBM22, SET, SPTLC1 and SPTBN1 ( Figure 3B ). Deleting the miR-145 seed sequence from some of these plasmids could rescue the luciferase activity. On the other hand, one of the proteins upregulated by miR-145 was claudin-11, which is a critical component of tight junctions. We observed a 2.4-fold claudin-11 protein increase and postulated that miR-145 could inhibit invasiveness of cancer cells through the tumor suppressive network including upregulated claudin-11 and suppressed FSCN1 among others. We employed a matrigel invasion assays to functionally examine the effects of miR-145 on cell migration of MiaPaca-2 pancreatic cancer cells. Forty-eight hours after transfection of miR-145/scrambled RNA control, we observed that miR-145-overexpressing pancreatic cancer cells were less capable of penetrating the matrigel membrane ( Figure 4 ).
Integration of transcriptome and proteome and effect of miR-145 target sites on mRNA/protein levels
To elucidate miRNA-mediated regulation on gene expression, two molecular mechanisms have been proposed, including transcript destabilization and translational repression. [66] [67] [68] In transcript destabilization, miRNAs and the RNA-induced silencing complex base-pair with mRNAs, leading to degradation of the regulated transcripts and subsequent downregulation of protein abundance. In translational repression, however, the engagement between miRNAs and mRNAs aborts translational initiation or halts translational elongation, causing decreased protein abundance without a concordant transcript degradation. To interrogate the contribution of each mechanism, we integrated the transcriptomic and proteomic changes caused by miRNA-145 and examined the correlation between these two datasets. There were 2,525 transcript/protein pairs in this study, and the overall correlation between transcript and protein fold changes was low (r=0.21, p<0.01) ( Figure 5 ). This level of correlation was close to other miRNAtransfection studies and lower than that reported by Schwanhausser et al which was focused on unperturbed mammalian cells. 66, [68] [69] [70] Of these 2,525 pairs were 13 known miR-145 targets according to TarBase 6.0, and the concordant mRNA/protein foldchanges were observed in 9 out of these 13 pairs: FSCN1, YES1, GMFB, APH1A, CBFB, CLINT1, AP1G1, NIPSNAP1, PODXL. On the other hand, these 2,525 transcript/protein pairs contained 1,110 pairs that had discordant mRNA and protein changes, i.e. the transcript level was upregulated while the protein abundance was downregulated or vice versa. In all discordant pairs, we noticed enrichment of molecules in the EIF2 signaling and protein ubiquitylation pathways (p=9.2E-31 and 1.26E-11, respectively) with the majority of these pathway components being suppressed at the protein level (Table S4 and S5). It is known that the "seed sequence" of a miRNA, i.e. nucleotides 2-7 at the 5' ends, is important for its targeting specificity. 71 The seed sequence of a miRNA can basepair with different regions of an mRNA (5'UTR, coding sequence (CDS) or 3'UTR) in different complementarity: such as "6mer", "7mer-A1", "7mer-m8" or "8mer" target site matches. 72 In our study, seed sequence matches were enriched in miR-145-downregulated mRNA transcripts (odds ratio 1.69, p=4.2E-10) and miR-145-downregulated proteins (Table 1) .
Furthermore, we evaluated the transcriptomic and proteomic changes related to different types of miR-145 target sites in 3'UTR, including 8mer, 7mer-m8, 7mer-A1, and 6mer sequences. We found that 8mer matching correlated with downregulation of transcript and protein levels (p=4.7E-12 and 4.7E-5, respectively) ( Figure 6 ) whereas other types of target sites only affected transcript levels but not protein levels ( Figure 7A ). We correlated these miRNAs with their predicted mRNA/protein pairs, which exhibit a concordant change in our dataset. Interestingly, the mRNA/protein pairs targeted by the upregulated miRNAs had lower TargetScan total context scores than those targeted by downregulated miRNAs (p=0.05, Figure 7B ). If only those pairs with protein fold change ≥1.5 were considered, the p-value was <0.01. In other words, miRNAs upregulated by miR-145 were predicted to repress their targets' protein abundance, suggesting that the proteomic change unexplained by miR-145 transfection could result from alteration of levels of other miRNAs.
Conclusions
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The advent of high-throughput technologies has expanded our ability to study complex biological systems. A multi-omics analysis enables even fuller characterization of biological intricacies. In this study, we took advantage of this systems approach to uncover novel aspects of miR-145-mediated pathway regulation. Through transcriptomic analysis in which we profiled mRNAs and miRNAs, we identified several unreported transcripts targeted by miR-145 along with a miRNA expression signature in multiple malignancies. To supplement bioinformatics and transcriptomic analysis, SILAC-based quantitative proteomics integrated into this study revealed novel miR-145 targets that were not revealed through transcriptomic analysis alone. In summary, novel targets and regulatory networks from this study help further our understanding about miR-145-mediated tumor suppression, and we believe this multi-omics analysis will advance biological research in other systems.
Experimental section Cell culture, SILAC labeling and miRNA transfection
A pancreatic cancer cell line, MiaPaca-2, was maintained in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with L-glutamine, 10% FBS, 100 U ml -1 penicillin and 100 µg ml -1 streptomycin. Growth of these cells were incubated in 5% CO 2 at 37°C and adapted to the SILAC media as described earlier. 77 The heavy medium was labeled with 
Protein extraction and in-gel digestion
Cells from scrambled RNA and miR-145 transfection were harvested in 2% SDS lysis buffer, homogenized and sonicated. Protein concentration was measured using Lowry assay. Equal amount of protein from control and miR-145-transfected samples were mixed and ~200 µg was loaded on SDS-PAGE. The gel was stained with colloidal Coomassie blue. The protein bands were excised and were subjected to in-gel digestion, as described previously. 78 Briefly, proteins were reduced using 5 mM dithiothreitol in 40 mM ammonium bicarbonate in 40% acetonitrile at 60°C for 20 minutes and alkylated using 20 mM iodoacetamide in 40% acetonitrile. In-gel trypsin digestion was carried out at 1:20 enzyme to protein ratio at 37°C overnight.
Strong cation exchange chromatography (SCX) and OFFGEL fractionation
Protein were reduced and alkylated with 5mM DTT and 10 mM iodoacetamide, respectively. In-solution trypsin digestion was carried out at 1:20 enzyme to protein ratio overnight at 37ºC. The peptides were fractionated by SCX. 79 
Gene expression and miRNA microarray analysis
One µg total RNA was used on Agilent-014850 Whole Human Genome Microarray platform (4x44K G4112F). miR-145-transfected and control samples were analyzed in dye-swap duplicates (Pearson correlation coefficients were 0.99 and 0.99, respectively).
One-hundred ng total RNA was used on Agilent's-Human miRNA Microarray platform (V3). Samples were collected 24 and 48 hr after miRNA transfection and were analyzed in duplicate. Raw data were pre-processed using the R package "Limma". 80 Brief, for the gene expression microarray experiments, normalization within arrays was carried out
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Molecular BioSystems Accepted Manuscript using "Loess" method and normalization between arrays was carried out using the "Scale" method. For the miRNA microarray experiments, normalization between arrays was carried out with the "Quantile" method. Both microarray analyses were performed using a generalized linear model approach, coupled with empirical Bayes shrinkage of standard errors. 80 Adjustment for multiple testing was achieved using the Benjamini and Hochberg method. 81 Raw data and analyses were uploaded to Gene Expression Omnibus at the National Center for Biotechnology Information with the accession numbers: GSE45245
for gene expression microarray and GSE45246 for miRNA microarray. Luciferase assays were carried out using the Dual-Luciferase® Reporter Assay System (Promega, San Luis Obispo, CA). The miR-145 seed sequence in 3'UTR was deleted using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent). Firefly luciferase activity was normalized to Renilla luciferase activity for each transfected well. For each experimental trial, cells were transfected in triplicate. For each 3'UTR construct, the ratio of miR-145 mimic to scrambled RNA oligos was calculated.
Invasion assays
Growth factor-reduced Matrigel invasion chambers (BD) were used according to the manufacturer's instructions. Briefly, MiaPaca-2 cells (5 x 10 4 ml -1 in DMEM+0.1% FBS)
in invasion chambers were transferred and exposed to the chemoattractant DMEM+5%
FBS. Forty-eight hours later, non-invasive cells were wiped off using cotton swabs.
Invasive cells were fixed in 10% formalin for 5 minutes, and then the Matrigel membranes were cut and mounted in DAPI to count cell nuclei.
Bioinformatics and statistical analysis
A web-based bioinformatics tool was developed in house for analyzing miRNA binding sites. All statistics analyses were performed in R 2.14 (64-bit 
